Advaxis (ADXS) Stock Price Down 5.4%

Shares of Advaxis, Inc. (NASDAQ:ADXS) fell 5.4% during trading on Tuesday . The company traded as low as $1.91 and last traded at $1.94. 574,585 shares changed hands during trading, a decline of 52% from the average session volume of 1,196,589 shares. The stock had previously closed at $2.05.

A number of research firms have recently commented on ADXS. HC Wainwright set a $23.00 target price on shares of Advaxis and gave the stock a “buy” rating in a research note on Wednesday, December 27th. Cantor Fitzgerald set a $19.00 target price on shares of Advaxis and gave the stock a “buy” rating in a research note on Thursday, December 28th. Finally, ValuEngine raised shares of Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

How to Become a New Pot Stock Millionaire

The stock has a market capitalization of $107.24, a PE ratio of -0.82 and a beta of 1.06.

Advaxis (NASDAQ:ADXS) last posted its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.06. The firm had revenue of $2.06 million for the quarter, compared to analyst estimates of $3.03 million. Advaxis had a negative net margin of 940.64% and a negative return on equity of 149.14%. research analysts forecast that Advaxis, Inc. will post -1.73 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Voya Investment Management LLC boosted its position in Advaxis by 20.3% during the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 2,975 shares during the last quarter. Wells Fargo & Company MN boosted its position in Advaxis by 39.9% during the fourth quarter. Wells Fargo & Company MN now owns 66,206 shares of the biotechnology company’s stock worth $187,000 after acquiring an additional 18,892 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Advaxis by 10.4% during the second quarter. The Manufacturers Life Insurance Company now owns 31,431 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 2,969 shares during the last quarter. Cutler Capital Management LLC boosted its position in Advaxis by 150.0% during the third quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 30,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Advaxis during the second quarter worth about $352,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Advaxis (ADXS) Stock Price Down 5.4%” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.thestockobserver.com/2018/03/20/advaxis-adxs-stock-price-down-5-4.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply